KKRFinancial Services · Asset ManagementThe 23 Wall Street analysts covering KKR & Co., Inc. hold a median 12-month price target of $120 — +27.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 29 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores KKR & Co., Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (92): Sales and profits are climbing, and climbing faster than before.
Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on KKR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +27.1% from it.
Of the 20 most recent actions, 4 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | BMO Capital | Maintains | Outperform | $118 → $109 |
| 26 Oct 2026 | Barclays | Maintains | Overweight | $130 → $127 |
| 19 Oct 2026 | Piper Sandler | Maintains | Overweight | $128 → $121 |
| 19 Oct 2026 | Piper Sandler | Maintains | Overweight | — |
| 13 Oct 2026 | UBS | Maintains | Buy | $123 → $122 |
| 13 Oct 2026 | UBS | Maintains | Buy | — |
| 12 Oct 2026 | TD Cowen | Maintains | Hold | $118 → $103 |
| 12 Oct 2026 | TD Cowen | Maintains | Hold | — |
| 8 Oct 2026 | Barclays | Maintains | Overweight | $135 → $130 |
| 8 Oct 2026 | Barclays | Maintains | Overweight | — |
| 2 Oct 2026 | Wells Fargo | Initiates | Equal-Weight | $97 |
| 2 Oct 2026 | Wells Fargo | Initiates | Equal-Weight | — |
| 27 Aug 2026 | Oppenheimer | Maintains | Outperform | — |
| 27 Aug 2026 | Oppenheimer | Maintains | Outperform | $139 → $166 |
| 4 Aug 2026 | Argus Research | Maintains | Buy | $115 → $125 |
| 4 Aug 2026 | Argus Research | Maintains | Buy | — |
| 3 Aug 2026 | BMO Capital | Maintains | Outperform | $112 → $118 |
| 3 Aug 2026 | BMO Capital | Maintains | Outperform | — |
| 3 Aug 2026 | TD Cowen | Maintains | Hold | $108 → $111 |
| 3 Aug 2026 | TD Cowen | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KKR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, KKR & Co., Inc. returned −19.5% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 26% of US stocks
Cheaper than 36% of US stocks
Cheaper than 32% of US stocks
Cheaper than 7% of US stocks
Higher than 47% of US stocks
Higher than 70% of US stocks
Higher than 20% of US stocks
Higher than 80% of US stocks
Higher than 74% of US stocks
Higher than 57% of US stocks
Higher than 54% of US stocks
Higher than 69% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
KKR & Co., Inc. has a market value of $88.5B and an enterprise value of $146.6B.
Revenue in the twelve months to 30 June 2026: $21.1B. The latest quarter grew 7.8% year on year.
Net income over the same four quarters: $5.5B, a 26.2% net margin.
Diluted earnings per share, trailing twelve months: $3.14.
Free cash flow in the twelve months to 30 June 2026: $2.3B.
KKR & Co., Inc. spent $233.2M on share buybacks and $831.3M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 30.3×; forward P/E: 13.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.83%, paying out 24% of earnings.
KKR & Co., Inc. employs 5,043 people — $4.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own KKR & Co., Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
KKR-advised capital accounts and Alexandria Real Estate Equities announced a $475 million joint venture investment in Alexandria’s majority ownership interest in Campus Point, a nearly 2 million-square-foot life science campus in San Diego.
Why it matters — The investment adds a sizable life science real estate joint venture involving KKR-advised capital to the firm’s reported activity.
Ben & Jerry’s founders have been exploring a deal with a KKR executive that would separate the brand from Magnum, which was spun out of Unilever. Magnum says Ben & Jerry’s is not for sale.
Why it matters — The reported discussions involve a KKR executive and a potential transaction concerning Ben & Jerry’s.
KKR appointed Brian J. Lee, former Chief Risk Officer of The Goldman Sachs Group, Inc., to its Board of Directors effective October 26, 2026. His appointment brings the number of independent directors to eight of the Board’s 12 seats.
Why it matters — KKR watchers may note the change in the Board’s composition and the number of independent directors.
The article says leading alternative asset managers have fallen nearly 50% from their highs and points to AI and infrastructure investments as potential growth drivers. It also notes that valuations are historically low.
Why it matters — KKR watchers may consider the article’s sector-wide discussion of declines, valuations and potential growth drivers relevant to the company.
KKR agreed to acquire the Explosion Protection and Static Control segments from HOERBIGER, including IEP Technologies and Newson Gale. The deal represents the majority of HOERBIGER’s Safety Business Unit.
Why it matters — The agreement adds two industrial safety solution providers to KKR’s portfolio.
The 23 Wall Street analysts covering KKR & Co., Inc. have a median 12-month price target of $120, with estimates ranging from $97 to $163. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 23 analysts covering KKR & Co., Inc., 20 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks KKR & Co., Inc. 58 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 29 Oct 2026, KKR & Co., Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).
No one can know that. What the data says: the median 12-month target from 23 analysts implies +27.1% from the last close, and Ticker Nerd's factor model ranks KKR & Co., Inc. 58 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering KKR & Co., Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KKR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $97 to $163 over the next 12 months.
KKR & Co., Inc. returned -19.5% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-editing genetic medicines for rare and more common diseases.
The most recent item we track (Business Wire, 28 Oct 2026): "KKR Invests $475 Million in Alexandria Real Estate Equities' Campus Point". KKR-advised capital accounts and Alexandria Real Estate Equities announced a $475 million joint venture investment in Alexandria’s majority ownership interest in Campus Point, a nearly 2 million-square-foot life science campus in San Diego.
Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-editing genetic medicines for rare and more common diseases. The company’s programs are designed to make precise changes at the RNA level, aiming to address disease-causing biology without permanently altering DNA. Its current pipeline includes lead candidate KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide under development for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy, along with additional research programs in liver and other therapeutic areas. Korro Bio’s platform is built around programmable RNA editing and oligonucleotide-based delivery, positioning the company within the growing field of next-generation genetic medicines. Based in Cambridge, Massachusetts, Korro Bio focuses on discovery and development activities across its research and clinical-stage portfolio.
CEO Mr. Joseph Y. Bae · 5,043 employees · United States · https://www.kkr.com
